Dechra Pharmaceuticals (LON:DPH)‘s stock had its “add” rating reaffirmed by investment analysts at Numis Securities in a report released on Friday. They presently have a GBX 2,640 ($37.07) price objective on the stock. Numis Securities’ price target would indicate a potential upside of 10.83% from the stock’s current price.
Several other research firms have also issued reports on DPH. Royal Bank of Canada lowered shares of Dechra Pharmaceuticals to a “sector performer” rating and raised their price target for the stock from GBX 2,200 ($30.89) to GBX 2,400 ($33.70) in a report on Thursday. Jefferies Group upgraded shares of Dechra Pharmaceuticals to a “buy” rating and raised their price target for the stock from GBX 2,221 ($31.19) to GBX 2,631 ($36.95) in a report on Tuesday. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of GBX 2,121.17 ($29.79).
Dechra Pharmaceuticals (DPH) traded up GBX 42 ($0.59) during trading on Friday, reaching GBX 2,382 ($33.45). 214,609 shares of the company’s stock traded hands, compared to its average volume of 152,604. Dechra Pharmaceuticals has a 52-week low of GBX 1,440 ($20.22) and a 52-week high of GBX 2,458 ($34.52). The company has a market cap of $2,230.00 and a price-to-earnings ratio of 8,507.14.
Dechra Pharmaceuticals PLC is engaged in veterinary pharmaceuticals and related products business. The Company is engaged in development, manufacture and marketing of products for veterinarians. Its segments include European Pharmaceuticals, North American (NA) Pharmaceuticals and Pharmaceuticals Research and Development.
Receive News & Ratings for Dechra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dechra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.